HOTH: Hoth Therapeutics, Inc. Stock

by  •  • Comments Off on HOTH: Hoth Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.52
Enterprise Value ($M) -2.50
Book Value ($M) 7.49
Book Value / Share 1.09
Price / Book 0.74
NCAV ($M) 7.42
NCAV / Share 1.08
Price / NCAV 0.74

Profitability (mra)
Return on Invested Capital (ROIC) -1.00
Return on Assets (ROA) -0.62
Return on Equity (ROE) -0.71

Liquidity (mrq)
Quick Ratio 10.16
Current Ratio 10.16

Balance Sheet (mrq) ($M)
Current Assets 8.24
Assets 8.31
Liabilities 0.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc 4.99 57.96

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2024 ☐ TRANSITION REP
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 ☐ TRANSITION REPORT
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-27 35,362 118,886 29.74
2024-11-26 29,595 143,061 20.69
2024-11-25 152,358 494,637 30.80
2024-11-22 53,297 355,769 14.98

(click for more detail)

Similar Companies
GYRE – Gyre Therapeutics, Inc. HEPA – Hepion Pharmaceuticals, Inc.
HOOK – HOOKIPA Pharma Inc. HRTX – Heron Therapeutics, Inc.
ICCC – ImmuCell Corporation


Financial data and stock pages provided by
Fintel.io